Why DiaMedica Therapeutics Inc.’s (DMAC) Stock Is Down 5.01%
As of Thursday, November 19, DiaMedica Therapeutics Inc.’s DMAC share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Tudor Pop
Tudor Pop
Jenna Brashear
Michael Rose
| Share Statistics | DMAC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $463.5 | $213.9 | 38% |
|
| Shares Out (Mil) | 53.9 | 55.4 | 49% |
|
| Institutional Ownership | 31.2% | 93.3% | 12% |
|
| Float (Mil) | 25.3 | 40.6 | 32% |
|
| Beta | 0.94 | 0.98 | 55% |
|
| Avg Daily Volume (000s) | 206 | 597 | 45% |
|
| Price Change (52-week) |
34.0% | 40.9% | 79% |
|
| Growth | DMAC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (21.7%) | (10.7%) | 19% |
|
| EPS (5yr) | 2.3% | 15.5% | 35 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 4.2% | (15.7%) | 67% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.240) | ($0.823) | ($0.768) | |
| Month Ago EPS | ($0.223) | ($0.813) | ($0.808) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.223) | ($0.813) | ($0.808) | |
| Year/Year Chg | 14.3% | 18.1% | 39.9% | |
| Financials | DMAC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($40) | ($44) | 18% |
|
| EPS (TTM) | ($0.752) | ($1.400) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($34) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $-0 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $440 | $135 | 34% |
|
| Valuation | DMAC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 16.21 | 1.97 | 95% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | DMAC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (86.3%) | (47.5%) | 6% |
|
| ROE | (100.2%) | (51.9%) | 9% |
|
| Liabilities to Assets | 20.7% | 29.7% | 13% |
|
| F-Score | 2 | 3 | 7% |
|
DiaMedica Therapeutics Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors